R&D | April 22, 2026
Pfizer unleashes wave of breakthrough cancer data at ASCO 2026
Pharma giant targets new standards of care
Pharma giant targets new standards of care
By cutting pain crises & boosting haemoglobin
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
A brand from Opella will be part of the official NASA astronaut formulary
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Subscribe To Our Newsletter & Stay Updated
